Novozymes Biopharma's Technology Demonstrates Potential for Monthly Drug Dosing - - BioPharm International

ADVERTISEMENT

Novozymes Biopharma's Technology Demonstrates Potential for Monthly Drug Dosing


Novozymes Biopharma has released new study data on extending the serum half-life of albumin in vivo. Results, presented at PepTalk 2014, demonstrate the ability of Novozymes’ half-life extension platform to prolong the therapeutic half-life of drug candidates, which could potentially reduce the dosing frequency as a result. The technology offers drug developers an attractive approach for optimizing the serum half-life of biopharmaceuticals as well as the possibility for monthly dosing.

By modifying the human albumin molecule, Novozymes managed to alter the affinity of albumin to the FcRn receptor. Extended serum half-life was observed for a range of albumin variants. The platform has the potential to provide patients with better quality of life through tailoring drug circulatory half-life to meet specific medical needs, while improving patient compliance and reducing healthcare costs.

Source: Novozymes

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here